11 results about "Megakaryocyte" patented technology

The invention provides a reagent composition for detecting minimal residual diseases of acute megakaryocytic leukemia and application of the reagent composition. The reagent composition comprises two groups of antibodies and is a flow cytometry detection composition for follow-up visit of minimal residual diseases after acute megakaryocytic leukemia treatment, a two-tube parallel scheme is used during application, and the first group of antibodies and the second group of antibodies are respectively used for different tube samples. The reagent composition can be applied to flow cytometry to detect minimal residual diseases after acute megakaryocytic leukemia treatment.

A method of selectively modulating gene expression of one or more target genes in megakaryocytes, circulating platelets, and / or platelets generated by the transfected megakaryocytes, in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of composition comprising naked RNA oligonucleotides.

The present application provides a kind of acute megakaryocyte leukemia micro residual disease detection reagent composition and its application.The reagent composition includes two groups of antibodies, and is used for the composition of flow cytometry detection for following-up micro residual disease after the treatment of acute megakaryocyte leukemia, and when used, 2 tubes are used in parallel, wherein the first group of antibodies and the second group of antibodies are used for different tube samples respectively.The reagent composition of the present application can be applied to flow cytometry detection of micro residual disease after the treatment of acute megakaryocyte leukemia.

Methods of production and apparatuses for production for stably producing healthy and functional platelets, and methods for determining operating conditions of an apparatus for producing platelets are provided. The present invention relates to methods of production comprising a step of culturing megakaryocytes in a platelet production medium C, wherein the step of culturing comprises a step of stirring a medium C in containers 1, 4 using stirring mechanisms 2, 5. In one method of production, the step of stirring comprises reciprocating stirring blades 21, 24 in the stirring mechanisms 2, 24 such that any of predetermined turbulent energy, shearing stresses, or Kolmogorov scale is produced, in the medium C. In another method of production, the step of stirring comprises pivoting a stirring blade 51 in the stirring mechanism 5 wherein a plurality of stationary members 53 is placed therearound in a bottom region 4e of the container 4 such that the step of stirring produces turbulence in the medium C. The present invention also relates to apparatuses for production for carrying out the method of production. The present invention also relates to a method for determining operating conditions of an apparatus for producing platelets.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound Aglaroxin C in preparation of an erythroleukemia induced differentiation treatment medicine. The compound Aglaroxin C disclosed by the invention has the activity of resisting erythroleukemia cells HEL and K562, and the proliferation of the HEL and K562 cells is inhibited by inducing the HEL and K562 cells to generate G2 phase cycle arrest and cell apoptosis. According to the Aglaroxin C disclosed by the invention, the grain sizes of HEL and K562 cells are induced to become larger, multinuclear cells are remarkably increased, and meanwhile, the expression of a surface marker differentiated from a megakaryocyte line is promoted, so that the HEL and K562 cells are promoted to differentiate to the megakaryocyte line.

The present application provides a method for inducing differentiation of embryonic stem cells into megakaryocytes. The provided method comprises the step of inducing differentiation of engineered embryonic stem cells into megakaryocytes; the engineered embryonic stem cells express a reduced amount of SHMT2 protein compared to unengineered embryonic stem cells. Megakaryocytes and platelets can be efficiently prepared via the method.

This invention relates to the field of platelet production technology, and in particular to a method for producing platelets based on biomimetic microcarriers. The method overcomes the key bottlenecks of low in vitro platelet yield, incomplete function, and difficulty in large-scale production in the prior art. By constructing a biomimetic bone marrow-vascular wall microenvironment, it systematically solves the technical problem of low yield of megakaryocytes in in vitro culture systems, and provides a brand-new solution for the safe, efficient, and economical in vitro preparation of platelets.

The invention pertains to methods for the production of polyploid megakaryocytes using diploid megakaryocytes derived from induced pluripotent stem cells (iPSCs), the polyploid megakaryocytes so produced, and their use for the production of iPSC-derived platelet-like particles. The invention further pertains to the iPSCs-derived platelet-like particles produced using the polyploid megakaryocytes of the invention, and their use as a medicament.

The invention discloses a method for inducing hematopoietic stem / progenitor cells into myeloid progenitor cells and a culture medium used in the method. The method comprises a three-stage induced differentiation strategy of hematopoietic stem cells-pluripotent progenitor cells-myeloid progenitor cells, wherein a first-stage culture medium takes low-concentration cell factors and small molecule components as main components, and mainly promotes enrichment and amplification of the hematopoietic stem cells and enables the hematopoietic stem cells to smoothly transit to an in-vitro culture environment; the second-stage culture medium takes high-concentration cell factors and small molecules as main components and mainly promotes amplification of pluripotent progenitor cells and induced differentiation of common myeloid progenitor cells; in the third stage, the culture medium takes high-concentration cell factors, myeloid induction factors and small molecules as main materials to promote efficient amplification of three kinds of myeloid progenitor cells including common myeloid progenitor cells, granulocyte mononuclear myeloid progenitor cells and megakaryocyte erythroid myeloid progenitor cells, and finally a myeloid progenitor cell product is obtained. The myeloid progenitor cell amplification method provided by the invention greatly improves the induced amplification efficiency of the myeloid progenitor cells, and has very high clinical transformation application potential.

The present invention provides a method of high-density cell culture comprising at least the following steps: S1: obtain hydrogel microcapsules through membrane emulsification; S2: encapsulate a selected number of cells per each obtained hydrogel microcapsule, and S3: culture the encapsulated cells in a cell culture medium. The invention further refers to Human Pluripotent Stem Cells (hPSCs) obtained through the above-described method, in particular for use in medicine, more in particular for use in a method of in vitro generation of mature megakaryocytes.

The invention discloses a method for detecting megakaryocytes in a bronchopulmonary dysplasia model, and relates to the field of biomedicine. Comprising the following steps: constructing a BPD mouse model, carrying out HE staining, flow cytometry and immunofluorescence detection on lung tissues, and analyzing the number, proportion, ploidy and distribution of megakaryocytes, the construction of the BPD mouse model comprises the following steps: randomly dividing C57BL / 6j strain newborn mice into an experimental group and a control group one day after the newborn mice are born, feeding the experimental group in a 85-90% high oxygen concentration environment for 14 days, and feeding the control group in a C57BL / 6j strain newborn mice in a C57BL / 6j strain newborn mice in a C57BL / 6j strain newborn mice. The control group is fed in the air, and the female rats are interchanged among the groups every 24 hours. By integrating model construction, HE staining, flow cytometry and immunofluorescence, multi-dimensional detection of megakaryocytes in the BPD model is achieved, the method is standardized and good in repeatability, reduction and ploidy change of megakaryocytes in lung tissue can be accurately reflected, and a reliable tool is provided for research of a BPD mechanism.